GlassScriptPhysician profile
Shamsher Lakhian
NPI 1104879907
$21,121.07
in general payments reported to CMS, 2019-2025
54 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,632 · 2020: $3,847 · 2021: $4,829 · 2022: $1,599 · 2023: $2,082 · 2024: $1,460 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.32 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,673.71 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $4,314.09 | 2019-2024 | Afrezza |
| Novo Nordisk INC | $2,558.65 | 2019-2025 | Rybelsus, Ozempic, Sogroya |
| Amgen INC. | $1,106.25 | 2019-2025 | Prolia, Evenity, Tepezza |
| Astrazeneca Pharmaceuticals LP | $670.17 | 2019-2023 | Farxiga |
| Abbott Laboratories | $613.11 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $557.49 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.68 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $521.01 | 2019-2024 | Baqsimi, Lyumjev, Jardiance |
| Abbvie INC. | $520.48 | 2019-2024 | |
| Insulet Corporation | $511.51 | 2020-2024 | Omnipod |
| Radius Health, INC. | $380.38 | 2020-2024 | Tymlos |
| Esperion Therapeutics, INC. | $363.75 | 2021-2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $362.56 | 2020-2024 | Gvoke Hypopen |
| Dexcom, INC. | $330.51 | 2019-2024 | Dexcom G6 Transmitter |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamsher Lakhian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.